Safety and Efficacy Updates from a Phase 1 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Safety, Efficacy, and Patient-Reported Outcomes with Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Who Received Prior Anti-Colony-Stimulating Factor 1 Therapy: Ongoing Phase 2 Update

The MOTION study: a randomized, Phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.

Safety and efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT): Long-term phase 1 update.

Presentation of New Clinical Study Results from DCC-3116 and Vimseltinib at the European Society for Medical Oncology (ESMO) Congress 2022.

Efficacy and safety of vimseltinib in tenosynovial giant cell tumor (TGCT): Phase 2 expansion.

Presentation of New Clinical Study Results from Rebastinib and Vimseltinib at the European Society for Medical Oncology (ESMO) Congress 2021.

Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT).

Vimseltinib: A precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages.

Discovery of vimseltinib (DCC -3014), a highly selective switch -control inhibitor of CSF1R kinase.